clinicaladvisor.com3d
FDA Approval Increases Eligibility for Cystic Fibrosis Medication Trikafta
According to Vertex Pharmaceuticals, approximately 300 additional people with CF are now eligible to receive treatment.
Nasdaq16d
Vertex announces FDA exands approval for Trikafta
Vertex Pharmaceuticals (VRTX) announced the U.S. Food and Drug Administration has approved the expanded use of Trikafta for the treatment of people with cystic fibrosis ages 2 and older who have ...
STAT24d
South African regulator decides Vertex provides sufficient access to CF drugs, angering activists
generic versions of Trikafta, a particularly effective triple-combination treatment for the disease, which causes the body to produce thick, sticky mucus that damages the lungs and other organs.
Yahoo Finance14d
Vertex Secures FDA Approval for New Cystic Fibrosis Drug Alyftrek
The drug is also eligible for use in CF patients who have discontinued Trikafta or Vertex’s other CF medicines. Similar regulatory filings are also under review in Europe. However, the drug’s ...
Monthly Prescribing Reference10d
FDA Approval Increases Eligibility for Cystic Fibrosis Medication Trikafta
Trikafta is supplied in the following dosage strengths and formulations: Elexacaftor 50mg, tezacaftor 25mg, and ivacaftor 37.5mg with ivacaftor 75mg (tablet); Elexacaftor 100mg, tezacaftor 50mg ...